Griffon Q4 Adj. Profit From Cont. Ops. Rises; Revenue Up 24%

Griffon Corp. (GFF) reported fourth quarter adjusted income from continuing operations of $59.7 million, or $1.09 per share compared to $17.7 million, or $0.33 per share, prior year. On average, five analysts polled by Thomson Reuters expected the company to report profit per share of $0.78, for the quarter. Analysts' estimates typically exclude special items. Adjusted EBITDA from continuing operations was $125 million, increasing 135% from the prior year quarter of $53 million.

Loss from continuing operations in the fourth quarter was $415.4 million, or $7.97 per share, compared to income from continuing operations of $12.6 million, or $0.24 per share, prior year. The results included non-cash impairment charge of $454.8 million, net of tax, or $8.31 per share, related to goodwill and indefinite lived intangible assets in CPP segment.

Revenue was $709 million, increasing 24% from $570 million in the prior year. Analysts on average had estimated $708.66 million in revenue.

The company expects 2023 revenue of $2.95 billion and adjusted EBITDA of at least $500 million excluding items.

For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
IBSA Pharma Inc. is recalling 27 lots of TIROSINT-SOL (levothyroxine sodium) Oral Solution to the consumer level due to subpotency, the U.S. Food and Drug Administration said. TIROSINT-SOL is indicated for Hypothyroidism and Pituitary Thyrotropin (Thyroid-Stimulating Hormone, TSH) Suppression. Meanwhile, the recall does not apply to TIROSINT (levothyroxine sodium) capsules. The U.S. Food and Drug Administration approved GlaxoSmithKline LLC's Jesduvroq tablets (daprodustat) for anemia caused by chronic kidney disease or CKD for adults who have been receiving dialysis for at least four months. It is the first oral treatment for anemia, i.e., decreased number of red blood cells, in the given indication that has received FDA approval. German banking major Deutsche Bank AG reported Thursday a significantly higher profit in its fourth quarter and fiscal 2022, mainly reflecting a tax benefit in the U.S, despite weakness in Investment Bank and asset management revenues. The company said it recorded its highest annual profit, both before and after tax, since 2007. However, Deutsche Bank shares were losing around 4 percent...
Follow RTT